Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
2000 Turkeys
Roads, Travel and Traffic
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Jobs
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
2000 Turkeys
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Jobs
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
UBS Group AG Registered Ordinary Shares
(NY:
UBS
)
46.56
-1.05 (-2.21%)
Official Closing Price
Updated: 4:10 PM EST, Nov 17, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about UBS Group AG Registered Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Gilead Sciences Bets on HIV Prevention Growth Despite $1.5 Billion Biktarvy Headwind
↗
Today 8:12 EST
Gilead Sciences (NASDAQ:GILD) expects its expanding HIV prevention portfolio and a potential new cell therapy for multiple myeloma to support growth, even as a negotiated price change for its HIV...
Via
MarketBeat
Cytokinetics Touts MYQORZO Launch Momentum, Plans New FDA Filing
↗
Today 4:12 EST
Cytokinetics (NASDAQ:CYTK) executives said the company is seeing momentum in the launch of heart drug MYQORZO and is preparing to seek U.S. approval for its use in a second form of hypertrophic...
Via
MarketBeat
Ultragenyx Pharmaceutical Targets 2027 Profitability After Deep Cuts and Gene Therapy Launches
↗
Today 3:12 EST
Ultragenyx Pharmaceutical (NASDAQ:RARE) expects to reach profitability in 2027 as it cuts spending, expands sales of existing rare-disease treatments and launches two gene therapies, executives said at...
Via
MarketBeat
United Therapeutics Prepares for TYVASO Expansion After $833 Million Quarter
↗
November 16, 2026
United Therapeutics (NASDAQ:UTHR) is preparing for a potential expansion of its TYVASO franchise into idiopathic pulmonary fibrosis, while its executives pointed to strong third-quarter sales and a...
Via
MarketBeat
Ionis Pharmaceuticals Sticks to $3 Billion TRYNGOLZA Sales Goal Despite Slow Start
↗
November 16, 2026
Ionis Pharmaceuticals (NASDAQ:IONS) remains confident that its triglyceride-lowering drug TRYNGOLZA can generate more than $3 billion in peak annual U.S. sales, even as its launch has started more...
Via
MarketBeat
Nvidia Stock Might Have a Bigger Problem Than Replacing Jensen Huang. What Happens If It Loses 15% of Its Revenue?
↗
November 16, 2026
Analysts now warn that scrutiny in China could put up to 15% of Nvidia's revenue at risk.
Via
The Motley Fool
Axsome Therapeutics Sees AUVELITY Prescription Surge After Alzheimer’s Agitation Launch
↗
November 16, 2026
Axsome Therapeutics (NASDAQ:AXSM) executives said growth in new prescriptions for AUVELITY and an expanded sales team are positioning the company for further growth following the drug’s launch for...
Via
MarketBeat
BioMarin Pharmaceutical Sees $2.6 Billion Sales Potential in Amicus Drugs as VOXZOGO Expansion Looms
↗
November 16, 2026
BioMarin Pharmaceutical (NASDAQ:BMRN) expects growth from its acquired rare disease treatments, an expanded market for VOXZOGO and a pipeline that could deliver patient data in 2027, Chief Executive...
Via
MarketBeat
Vertex Pharmaceuticals Prepares for Key Kidney Drug Decision as Pipeline Readouts Loom
↗
November 16, 2026
Vertex Pharmaceuticals (NASDAQ:VRTX) is preparing for a Nov. 30 U.S. regulatory decision on its kidney disease treatment povetacicept, while awaiting clinical results across kidney disease, chronic...
Via
MarketBeat
Natera CFO Maps Multiple Paths to $6 Billion Revenue Target by 2029
↗
November 15, 2026
Natera (NASDAQ:NTRA) Chief Financial Officer Mike Brophy said the company has multiple paths to its $6 billion revenue target for 2029, citing growth in its Signatera cancer testing business and...
Via
MarketBeat
Butterfly Network CEO Sees Chip Revenue Dwarfing Ultrasound Device Business
↗
November 13, 2026
Butterfly Network (NYSE:BFLY) is expanding beyond its handheld point-of-care ultrasound business by licensing its semiconductor technology to other companies, CEO Joe DeVivo said during a discussion...
Via
MarketBeat
Topics
Intellectual Property
Elevance Health Targets 12% Earnings Growth in 2027 as Insurance Margins Recover
↗
November 13, 2026
Elevance Health (NYSE:ELV) expects adjusted earnings per share to grow at least 12% in 2027 from its recently increased 2026 baseline of at least $26.75, Chief Financial Officer Mark Kaye said at a UBS...
Via
MarketBeat
Topics
ETFs
Schrodinger Eyes Growth From AI Assistant Bunsen and Hosted Software Shift
↗
November 13, 2026
Schrodinger (NASDAQ:SDGR) is looking to its artificial intelligence assistant Bunsen and a shift toward hosted software contracts to expand use of its molecular discovery platform, executives said at...
Via
MarketBeat
Topics
Artificial Intelligence
Shoulder Innovations Doubles Customer Growth, Sets Sights on Surgical Robotics
↗
November 13, 2026
Shoulder Innovations (NYSE:SI) is targeting high-volume shoulder surgeons with its implant system and planning technology while developing a portable surgical robot and considering expansion into...
Via
MarketBeat
Labcorp’s Lab Growth Surges as $125 Million Reimbursement Risk Looms
↗
November 13, 2026
Labcorp (NYSE:LH) Chief Financial Officer Julia Wang said strength in the company’s central laboratory business and diagnostic testing helped drive third-quarter growth, while management prepares for a...
Via
MarketBeat
UBS Thinks Rivian Stock Can Hit $17. Is It a Buy?
↗
November 13, 2026
Record growth, a potential turnaround, and a major financial challenge are pulling this EV stock in opposite directions. Here's what could determine where it goes next.
Via
The Motley Fool
This ETF Has Gained 23% This Year. Is It Still Worth Buying in 2026?
↗
November 13, 2026
Defensive sectors are making a comeback in 2026. This one seems particularly well-positioned for 2027.
Via
The Motley Fool
Topics
Artificial Intelligence
Bonds
ETFs
UBS Announces Redemption of Ten ETNs
November 12, 2026
From
UBS AG
Via
Business Wire
Rivian Just Earned a Buy Rating. Is Wall Street Seeing a Turning Point?
↗
November 12, 2026
Rivian just received an upgrade from Wall Street, but the reasoning behind the upgrade is important.
Via
The Motley Fool
Topics
Electric Vehicles
Why Advanced Micro Devices Stock Popped Today
↗
November 11, 2026
It's more than just CoreWeave's earnings beat that's lifting AMD stock today.
Via
The Motley Fool
Topics
Artificial Intelligence
Earnings
Mastering Investment Goals and Managing Expectations
November 11, 2026
Via
GlobePRwire
Topics
Retirement
Kelley Hart joins UBS as Financial Advisor in Westport, Connecticut
November 11, 2026
From
UBS Wealth Management USA
Via
Business Wire
Prediction: This Will Be Nvidia’s Stock Price By the End of 2027
↗
November 11, 2026
Nvidia has been in the news for the wrong reason lately, but investors shouldn't overlook the company's strong prospects and cheap valuation.
Via
The Motley Fool
Topics
Artificial Intelligence
Lloyds Banking Group Sees Slower 2027 Interest Income Growth as Competition Bites
↗
November 11, 2026
Lloyds Banking Group (NYSE:LYG) expects net interest income to grow at a mid-single-digit pace in 2027, slowing from this year as competition for loans and deposits continues, Chief Financial Officer...
Via
MarketBeat
Illumina Bets on Clinical Demand for Growth as Research Funding Uncertainty Persists
↗
November 10, 2026
Illumina (NASDAQ:ILMN) expects clinical demand and sequencing consumables to remain central to its growth strategy, even as research customers continue to face uncertainty over grant funding,...
Via
MarketBeat
Topics
Artificial Intelligence
UBS: 3 Key Takeaways for Long-Term Investors
↗
November 09, 2026
Proposed Swiss capital rules could constrain the bank's global expansion, even as integration progress unlocks shareholder returns.
Via
The Motley Fool
Topics
Earnings
Danaher CEO Sees Faster Growth Ahead, With AI and Acquisitions in Focus
↗
November 09, 2026
Danaher (NYSE:DHR) President and CEO Julie Sawyer Montgomery said the company is aiming for faster core growth and market share gains through stronger commercial execution, innovation and acquisitions,...
Via
MarketBeat
Topics
Artificial Intelligence
This Prediction-Markets Bet Ignites Worry On Wall Street
↗
November 09, 2026
JPMorgan Chase, UBS and Stifel downgraded DraftKings after it cut its outlook. The stock is trading at its lowest level since April 2023.
Via
Investor's Business Daily
CVR Energy, Liberty Energy, ProPetro, Green Plains, and Solaris Energy Infrastructure shares skyrocket, what you need to know
November 09, 2026
What happened? A number of stocks jumped in the morning session after crude oil prices fell as President Trump played down the chance of new strikes on Iran....
Via
StockStory
Topics
Government
ProFrac and Granite Ridge Resources stocks trade up, what you need to know
November 09, 2026
Via
StockStory
Topics
Energy
Government
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at
/week.
Subscribe Today